SNDX Q1 2022 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$0

Operating Income

-$37M

Net Income

-$37M

EPS (Diluted)

$-0.63

QoQ Revenue Growth

-100.0%

Cash Flow

Operating Cash Flow

-$42M

Free Cash Flow

-$42M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$422M

Total Liabilities

$48M

Stockholders' Equity

$375M

Cash & Equivalents

$189M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$379,000	-100.0%
Gross Profit	$0	$379,000	-100.0%
Operating Income	-$37M	-$27M	-35.7%
Net Income	-$37M	-$28M	-34.1%